Cochlear Implants
by Cochlear Guest Author

5 resources on CI standard of care to help you join the industry conversation

June 4, 2021
Share

International Consensus Paper

The world’s first international consensus on cochlear implant treatment for adults was published in JAMA Otolaryngology.1 The paper was authored by 31 hearing experts assisted by cochlear implant user and professional advocacy organizations. The publication is a major step forward in clarifying when cochlear implants (CI’s) are a treatment option for adults and a timely call to policymakers, insurance funding bodies as well as health professionals to better understand the importance of providing access to CI treatment for those who could benefit.

  1. Newly published: First-ever global consensus on use of cochlear implants in adults

Read about the first global consensus on the use of cochlear implants for the management of bilateral moderate to profound or moderate sloping to profound hearing loss in adults was published online on August 27, 2020 in JAMA Otolaryngology Head and Neck Surgery.

2. Journal Club – Standard of Care: International Consensus Paper

Check out this International Consensus Paper article review written by Dr. Brian Kaplan, Senior Vice President of Clinical Strategy & Innovation at Cochlear.

60/60 Guideline

Zwolan et al recommends that patients be considered for a cochlear implant candidacy evaluation (CICE) if they obtain a score less than or equal to 60% correct on an unaided monosyllabic word test in the better ear and if they demonstrate a PTA greater than or equal to 60 dB HL.2 The group is hopeful that this simple guideline will result in an increase in the number of patients who are referred for a traditional cochlear implant candidacy evaluation.

3. AudiologyOnline course: Standard of Care: International Consensus and Candidacy Evaluation for Cochlear Implant Use in Adults: An Audiological Perspective

This course focuses on the methodology and findings from a recent international systematic review and consensus process, establishing a standard of care for the treatment of adult patients with unilateral cochlear implant for bilateral severe, profound, or moderate sloping to profound sensorineural hearing loss. It also includes a review of “Terry Zwolan et al Development of a 60/60 Guideline for Referring Adults for a Traditional Cochlear Implant Candidacy Evaluation. Otology & Neurotology: April 20, 2020.”

4. Journal Club: Development of a 60/60 Guideline for Referring Adults for a Traditional Cochlear Implant Candidacy Evaluation

Read this journal club article discussing the new 60/60 Guideline and its importance.

5. New considerations for recommending a cochlear implant evaluation

Traditionally, cochlear implants have been considered a treatment option only for those who have lost all of their hearing. Read how the new 60/60 Guideline may change that.

Join this webinar series to learn more!

  1. Craig A. Buchman, et al., Unilateral Cochlear Implants for Severe, Profound, or Moderate Sloping to Profound Bilateral Sensorineural Hearing Loss. A Systematic Review and Consensus Statements. JAMA Otolaryngol Head Neck Surg. doi:10.1001/ jamaoto.2020.0998 Published online August 27, 2020 ** Commentary and suggested implications is the work of the authors of the summary. EURO-CIU GLOBAL GUIDELINES ON STANDARDS OF CARE FOR ADULT COCHLEAR IMPLANTATION, Sue Archbold, Brian Lamb and Leo De Raeve.
  2. Zwolan, Teresa A.; Schvartz-Leyzac, Kara C.; Pleasant, Terrence Development of a 60/60 Guideline for Referring Adults for a Traditional Cochlear Implant Candidacy Evaluation, Otology & Neurotology: April 20, 2020 – Volume Publish Ahead of Print – Issue – doi: 10.1097/MAO.0000000000002664

Author

Cochlear Guest Author

In an effort to keep our content fresh and reflective of a diverse industry, Cochlear Americas features a mix of employees and professional partners to contribute to Cochlear ProNews as Guest Authors.

View all posts

Related Posts
Android Robot

Introducing Custom Sound® 5.2

September 23, 2019
Nucleus 7

By Kyle Longwell, Product Manager – Software and Clinical Care

Cochlear is excited to announce the availability of Custom Sound® Suite 5.2 which will allow for expanded features in the Cochlear™ Nucleus® 7 sound processor.

Custom Sound 5.2 requires a database change and may require assistance from your IT department. So, in order to assist you and IT, we are offering software support sessions which are available through your Cochlear representative.

If you are ready to get started, the download link for Custom Sound 5.2 software can be found in the installation instructions located in the “Software Support” resource section of myCochlear Clinic.

It will be important to upgrade your fitting software in order to update the firmware on Nucleus 7 sound processors enabling access to Android direct streaming*.

What’s New in Custom Sound 5.2?


• Direct Android streaming
First for iPhone®. First for Android. Cochlear implant recipients with the Nucleus 7 sound processor and a compatible Android device* will be able stream audio directly to their Nucleus 7 processor without the need for the Cochlear Phone Clip.

A firmware update to the Nucleus 7 sound processor is required. The firmware update is delivered by connecting the sound processor to Custom Sound 5.2. Additionally, Nucleus 7 users will also need to update their Nucleus Smart App and make sure their compatible Android device has the Android 10.0 (Q) operating system.


• Nucleus Profile™ Plus implant compatibility
The new Nucleus Profile Plus implant offers patients access to 3.0 and 1.5 Tesla (T) MRI scans without the need for a head wrap or internal magnet removal.¹ Note that if you had previously entered the Nucleus Profile Plus implant Key into Custom Sound 5.1, you will not be required to enter the Key again, it will be accessible after upgrading to Custom Sound 5.2.

therwise, in order to program patients you will need to input the Authorization Key enabling access to this new implant in Custom Sound 5.2. To obtain the Key please reach out to your local Cochlear Americas representative or access instructions in the “Software Support” resource section of myCochlear Clinic.

Upon connecting the sound processor, a message will appear to remind you to use the correct magnet for the Nucleus Profile Plus implant.


• Other New Features
–Auto Pulse Width feature provides options for clinicians to automatically widen the pulse width on all channels and bring them back into compliance. This feature applies to all Nucleus 24, Freedom® and Profile series implants except for the Auditory Brainstem Implants (ABI124M and ABI541).

-The new software Auto-Update feature introduces a simplified way to roll out certain Custom Sound updates via the internet (i.e. when service release updates are needed to address minor bug fixes).

Download the new Custom Sound 5.2 software to enable your patients access to expanded connectivity offerings!


References:

  1. 1. MRI Guidelines D774756.

*The Cochlear Nucleus 7 Sound Processor is compatible with Apple and Android devices, for compatibility information visit www.cochlear.com/compatibility.

The Cochlear Nucleus 7 Sound Processor is compatible with iPhone, iPad and iPod touch. Apple, the Apple logo, FaceTime, Made for iPad logo, Made for iPhone logo, Made for iPod logo, iPhone, iPad Pro, iPad Air, iPad mini, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.

App Store is a service mark of Apple Inc., registered in the U.S. and other countries.

Android and Google Play are registered trademarks of Google Inc.
The Android robot is reproduced or modified from work created and shared by Google and used according to terms described in the Creative Commons 3.0 Attribution License.

The Cochlear Nucleus Smart App is available on App Store and Google Play. For complete smartphone compatibility information, please visit www.cochlear.com/compatibility.

Hearing 20/20

20/20 hearing makes it to Hollywood – The importance of knowing your PTA

August 2, 2021

By Patti Trautwein, MA, AuD, Vice President, Market Access & Reimbursement

What is normal hearing? When I asked that question among family, friends, and colleagues in early 2019 the answer was a sobering “I do not know.”  Yet, most could quickly rattle off measures for normal vision, blood pressure, cholesterol and body mass index. 1   

As hearing health professionals, we know how important the sense of hearing is to communicate and engage with others throughout one’s life. The COVID-19 pandemic requiring masking and social distancing has further highlighted the relevance of hearing health.2 Unfortunately, the lack of a common metric for hearing health, limits the understanding of consumers and primary care providers on how to prevent and treat hearing loss.

In a recent JAMA Otolaryngology–Head & Neck Surgery publication, Frank Lin, MD, PhD and Nicholas Reed, AuD, suggest that the otolaryngology and audiology community converge on the 4-frequency pure-tone average (PTA) as a universal metric for hearing health.3 Further, the 2021  World Report on Hearing from the World Health Organization defined grades of hearing loss using the PTA. 4

On world hearing day last year, a Hearing 20/20 campaign initiated public education on normal hearing using the PTA as a standard metric.

So, imagine the thrill receiving notes from family, friends and colleagues who recently watched the new movie The Hitman’s Wife’s Bodyguard with Samuel L Jackson, Salma Hayek and Ryan Reynolds where character Michael Bryce played by Ryan Reynolds states,“ I have 20/20 hearing, I can hear you.”

While diagnostically, we need a comprehensive battery to assess hearing function, the PTA as a simple, universal metric can help raise awareness of hearing health in the public vernacular on the big screen and hopefully off!

Read more about Hearing 20/20 here!

Patti

Patricia’s 25 years in the hearing healthcare industry includes roles in research and clinical studies, product management, education and training, sales and marketing. As Cochlear America’s VP of Market Access, Patricia is responsible for the reimbursement strategy of our product and service innovations, value-based evidence and economics, government affairs and related advocacy. Prior to her role in Market Access, Patricia served as the VP of Marketing, where she was responsible for the Marketing Strategy, Communications and Public Relations, Brand Ambassador Program and Product Management.

References:

  1. https://pronews.cochlear.com/what-is-normal-hearing-why-a-simple-and-consistent-answer-is-needed/
  2. https://www.hearingloss.org/hearing-loss-pandemic-survey/
  3. Lin FR, Reed NS. The Pure-Tone Average as a Universal Metric-Knowing Your Hearing. JAMA Otolaryngol Head Neck Surg. 2020 Dec 23. doi: 10.1001/jamaoto.2020.4862. Epub ahead of print. PMID: 33355634.
  4. https://www.who.int/publications/i/item/world-report-on-hearing
Cochlear logo - white

©Cochlear Limited 2024. All rights reserved. ACE, Advance Off-Stylet, AOS, Ardium, AutoNRT, Autosensitivity, Baha, Baha SoftWear, BCDrive, Beam, Bring Back the Beat, Button, Carina, Cochlear, 科利耳, コクレア, 코클리어, Cochlear SoftWear, Contour, コントゥア, Contour Advance, Custom Sound, DermaLock, Freedom, Hear now. And always, Hugfit, Human Design, Hybrid, Invisible Hearing, Kanso, LowPro, MET, MP3000, myCochlear, mySmartSound, NRT, Nucleus, Osia, Outcome Focused Fitting, Off-Stylet, Piezo Power, Profile, Slimline, SmartSound, Softip, SoundArc, True Wireless, the elliptical logo, Vistafix, Whisper, WindShield and Xidium are either trademarks or registered trademarks of the Cochlear group of companies. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

 

This material is intended for health professionals. If you are a consumer, please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always read the instructions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.

 

Cochlear ProNews is monitored Monday through Friday, excluding some holidays. Questions and inquiries submitted over the weekends or holidays may see a delay in response. For immediate assistance please contact us directly. You are solely responsible for your interactions with other members of our Websites. Cochlear reserves the right, but has no obligation, to monitor disputes or communications between you and other members of our Websites. For a full list of Cochlear’s terms of use, click here.